Amyndas Pharmaceuticals
  • Home
  • About
    • What We Do
    • Founder’s Bio
    • Management
  • Research & Development
    • Our Focus
    • Our Pipeline
    • Clinical Trials
    • Technology
    • Selected Publications
    • Notes on Targeted Conditions
  • News
  • Contact Us
  • LinkedIn
  • Twitter
  • Home
  • About
    • What We Do
    • Founder’s Bio
    • Management
  • Research & Development
    • Our Focus
    • Our Pipeline
    • Clinical Trials
    • Technology
    • Selected Publications
    • Notes on Targeted Conditions
  • News
  • Contact Us
  • LinkedIn
  • Twitter

Our Pipeline


Our Pipeline

Amyndas is developing the next generation Compstatins, compounds targeting complement inhibition on cell surfaces by Compsorbin, and compounds targeting complement inhibition using factor H mini constructs. For more information, see technology.

Latest News

  • Review: Compstatins: the dawn of clinical C3-targeted complement inhibition

  • JCI Video: Complement C3 Inhibitor AMY-101 in Adults with Periodontal Inflammation – Clinical Trial

  • Forsyth Dentech 2021: Presentation by Amyndas’ Managing Director Dr. Yancopoulou

  • JCI: Phase 2a clinical trial of complement C3 inhibitor AMY-101 in adults with periodontal inflammation

 

Latest Publications

  • Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis

  • Complement C3 vs C5 inhibition in severe COVID-19: early clinical findings reveal differential biological efficacy

  • The first case of COVID-19 treated with the complement C3 inhibitor AMY-101

  • Complement as a target in COVID-19?

 
 

Copyright © 2022 Amyndas Pharmaceuticals. All Rights Reserved.